tada - Here is your answer. The Apabetalone/Rosuvastatin combo had a highly statistical plaque reduction of p<0.002 (-1.43%) while the Apabetalone/Atorvastatin combo actually had plaque accumulation of 0.19% although this is such an insignificant amount that one would say there was no change. That is why RVX only wanted the Rosuvastatin combo and November 16th will tell us whether the FDA messed us up or RVX still didn't quite have a handle on this molecule as they couldn't duplicate or improve on those results with a better defined patient population.

Further to other thoughts of the value of the Rosuvastatin combo, I would say that if that combo has highly statistical successful data, it is just as valuable as if the trial had been successful. Unfortunately, it is a little harder to sell to the stock market, FDA and science world but can eventually be done. Atorvastatin's market share is shrinking and no longer that large so the APL/ROS combo could take most of the current statin market except for people that don't tolerate Atorvastatin. 

CALGARY, Sept. 3, 2013 /CNW/ - Resverlogix Corp. (TSX:RVX) today announced the Full Analysis Set (FAS) data from 281 treated patients in its Phase 2b ASSURE clinical trial evaluating RVX-208 using intravascular ultrasound (IVUS) in high-risk cardiovascular patients. Current findings show that the below median HDL (<39 mg/dL) baseline population consisted of 92 patients who were taking either Rosuvastatin (Crestor ) or Atorvastatin (Lipitor ) together with RVX-208. Those patients taking Rosuvastatin and RVX-208 had a highly statistically significant Percent Atheroma Volume (PAV) plaque regression of -1.43% with probability value of p<0.002. This PAV regression exceeded the trial's pre-specified PAV endpoint (-0.6%) by more than two-fold. But those patients taking Atorvastatin (Lipitor ) together with RVX-208 had a PAV plaque progression of +0.19% with a non-significant probability value. The synergistic effect of the Rosuvastatin and RVX-208 combination is the basis for two recent provisional patent applications by Resverlogix.